ArticleLiver cancer2022
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.
Article in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM.Frontiers in immunology · 2025Pooled it
- Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma.Liver cancer · 2026Article
- The China Paradox in LEAP-012 Trial.Liver cancer · 2026Article
- Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC.Liver cancer · 2026Article
- Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals.American journal of translational research · 2026Article
- Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.Journal of cancer research and clinical oncology · 2025Review
- Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study.The oncologist · 2025Article
- Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025Review
- TACE Empowers Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors in Unresectable HCC: A Multicenter Retrospective Study.Journal of Cancer · 2025Article
- Article
- Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma.Liver cancer · 2024Article
- Article
- Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?Journal of hepatocellular carcinoma · 2024Review
- Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.Liver cancer · 2023Article
- All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy.Liver cancer · 2023Article
- Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.Liver cancer · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.